In recent years, RA treatment has evolved, with biological disease-modifying anti-rheumatic drugs (DMARDs) such as TNF-α inhibitors, CTLA-4 inhibitors, and small molecule targeted DMARDs being recommended for patients who do not respond well to traditional DMARDs (54). This evidence concerns the gene CTLA4 and rheumatoid arthritis.